VolitionRx detects nucleosomes in sepsis patients using finger-prick lateral flow prototype study

VolitionRX Ltd

VolitionRX Ltd

VNRX

0.00
  • VolitionRx reported successful detection of nucleosomes in capillary blood from critically ill sepsis patients using a lateral flow finger-prick prototype.
  • Study, part of SUMMIT program, supports feasibility of rapid decentralized testing outside central laboratories, including bedside or emergency settings.
  • Full study details will be presented later this year, alongside commercialization updates.
  • Company framed finger-prick testing as an expansion of addressable market for sepsis diagnostics, citing about 166 million global sepsis cases.
  • Strategy targets partnerships to accelerate rollout in low-income countries where lab infrastructure is limited.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604290817PR_NEWS_USPR_____LN45616) on April 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.